<DOC>
	<DOCNO>NCT00534573</DOCNO>
	<brief_summary>Hypersalivation ( sialorrhea ptyalism ) know frequent , disturb , uncomfortable adverse effect clozapine therapy , enough effective treatment side effect lead noncompliance . In previous study find substitute benzamide derivatives high selective binding D2/D3 dopamine receptor - amisulpride sulpiride may effective treatment clozapine-induced hypersalivation ( CIH ) . Today , psychiatric practice Israel , four medication belong substitute benzamide derivative group : amisulpride , sulpiride , tiapride moclobemide . We hypothesize antisalivation effect universal whole group benzamide . The aim study compare efficacy amisulpride , moclobemide ( reversible monoamine oxidase inhibitor-A ( RIMAS ) ) , tiapride ( dopamine D2 antagonist ) additional possibility management CIH .</brief_summary>
	<brief_title>Benzamide Derivates Treatment Clozapine-induced Hypersalivation</brief_title>
	<detailed_description>The pilot study conduct two mental health center . In order examine hypothesis , use add-on design . Into study enrol 50 patient schizophrenia schizoaffective disorder ( male female , 19-60 year old ) , accord DSM-IV criterion , treat clozapine suffer hypersalivation .</detailed_description>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<mesh_term>Moclobemide</mesh_term>
	<criteria>Age 1860 year , male female DSMIV criterion schizophrenia Clozapine treatment At least 2 score Nocturnal Hypersalivation Rating Scale ( NHRS ) Evidence organic brain damage , mental retardation , alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>